Doxycycline Dose-dependently Inhibits MMP-2-Mediated Vascular Changes in 2K1C Hypertension

Spironolactone and hydrochlorothiazide exert antioxidant effects and reduce vascular matrix metalloproteinase-2 activity and expression in a model of renovascular hypertension

(2010) CS Ceron et al.   BRITISH JOURNAL OF PHARMACOLOGY

Antioxidant treatment reduces matrix metalloproteinase-2-induced vascular changes in renovascular hypertension

(2009) Michele M. Castro et al.   FREE RADICAL BIOLOGY AND MEDICINE

Imbalance between matrix metalloproteinases and tissue inhibitor of metalloproteinases in hypertensive vascular remodeling

(2009) Michele M. Castro et al.   MATRIX BIOLOGY

Chronic doxycycline exposure accelerates left ventricular hypertrophy and progression to heart failure in mice after thoracic aorta constriction

(2008) Laurent Vinet et al.   AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY

Evidence of early involvement of matrix metalloproteinase-2 in lead-induced hypertension

(2008) Elen Rizzi et al.   ARCHIVES OF TOXICOLOGY

Protective action of doxycycline against diabetic cardiomyopathy in rats

(2008) N Yaras et al.   BRITISH JOURNAL OF PHARMACOLOGY

Lercanidipine reduces matrix metalloproteinase-2 activity and reverses vascular dysfunction in renovascular hypertensive rats

(2008) Marcio L.L. Martinez et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Metalloproteinase inhibition ameliorates hypertension and prevents vascular dysfunction and remodeling in renovascular hypertensive rats

(2007) Michele M. Castro et al.   ATHEROSCLEROSIS

Matrix metalloproteinases and their inhibitors in vascular remodeling and vascular disease

(2007) Joseph D. Raffetto et al.   BIOCHEMICAL PHARMACOLOGY